Poison Control Reports Rise in GLP-1 Overdose Cases as Online Access Expands

Karleigh McClain was admitted to a hospital within 24 hours of receiving her first injection of a weight loss medication prescribed through a telehealth appointment. Her case represents one of a growing number of overdose reports involving GLP-1 drugs as these medications become available through online platforms with differing levels of medical oversight.

Poison control centers have tracked a measurable increase in calls related to GLP-1 medications over the past year. The surge corresponds with expanded access to these drugs through telehealth services, which connect patients with prescribers via video consultation and deliver medications by mail.

GLP-1 receptor agonists, originally developed to treat type 2 diabetes, gained widespread use for weight loss after clinical trials showed significant results. Brand names include Ozempic, Wegovy, and Mounjaro. The medications work by slowing gastric emptying and signaling fullness to the brain.

Several telehealth platforms now offer GLP-1 prescriptions following virtual consultations. Patients complete online questionnaires, speak with a healthcare provider, and receive prescriptions if approved. The medications arrive at their homes. The regulatory framework governing these services varies by state, creating different standards for medical evaluation, dosing guidance, and follow-up care.

Doctors at emergency departments report treating patients for complications including severe dehydration, acute kidney injury, and diabetic ketoacidosis. Some patients took higher doses than prescribed; others self-adjusted based on online guidance or peer recommendations. Several cases involved individuals without diabetes using the medications solely for weight loss.

The American Association of Poison Control Centers documented specific data on GLP-1 calls, though the organization did not release exact figures in recent statements. Individual poison centers in major metropolitan areas reported spikes ranging from double to triple their baseline volumes.

Pharmaceutical manufacturers have issued safety guidance recommending gradual dose escalation and regular medical monitoring. They emphasize that patients should receive prescriptions only from licensed healthcare providers and follow dosing protocols established during in-person or virtual clinical assessments.

Telehealth companies have implemented varying safeguards. Some require patients to report previous medication reactions, current prescriptions, and underlying health conditions. Others conduct basic screening but do not perform physical examinations or order baseline bloodwork. A few platforms employ registered nurses to review patient histories before physician approval.

State medical boards and the Food and Drug Administration have received complaints about prescribing practices. Some complaints alleged that providers authorized prescriptions after minimal consultation or without adequately assessing patient medical history. The FDA stated it monitors adverse event reports but has not issued a formal warning about telehealth GLP-1 prescribing.

Emergency physicians emphasize that GLP-1 overdoses present diagnostic challenges. Symptoms overlap with other conditions, and emergency departments do not stock specific antidotes. Treatment focuses on supportive care including intravenous fluids and electrolyte management.

Public health officials in several states have begun coordinating with telehealth companies to standardize prescribing requirements. Proposed measures include mandatory baseline kidney function tests, explicit dosing schedules with written confirmation, and required follow-up assessments at set intervals.

The surge in telehealth weight loss prescriptions reflects broader market expansion. Online platforms have captured significant market share from traditional dermatology and primary care practices that previously dominated weight loss medication prescribing. Patients cite convenience and faster access as primary reasons for choosing telehealth services.